{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:34:38Z","timestamp":1791588878418,"version":"4.3.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007219","name":"Shanghai Natural Science Foundation","doi-asserted-by":"crossref","award":["20ZR1411900"],"award-info":[{"award-number":["20ZR1411900"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shanghai Health Care Commission","award":["202040065"],"award-info":[{"award-number":["202040065"]}]},{"name":"Talents Training Program of Pudong Hospital affiliated to Fudan University","award":["LJ202101"],"award-info":[{"award-number":["LJ202101"]}]},{"name":"the Scientific Research Foundation provided by Pudong Hospital affiliated to Fudan University","award":["Zdxk2020-01"],"award-info":[{"award-number":["Zdxk2020-01"]}]},{"name":"the Scientific Research Foundation provided by Pudong Hospital affiliated to Fudan University","award":["Zdzk2020-09"],"award-info":[{"award-number":["Zdzk2020-09"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Recent studies have revealed an increase in the incidence rate of non-alcoholic fatty liver disease-related hepatocellular carcinoma (NAFLD-HCC). Furthermore, the association of Sphingosine 1-phosphate receptor 2 (S1PR2) with various types of tumours is identified, and the metabolism of conjugated bile acids (CBAs) performs an essential function in the onset and development of HCC. However, the association of CBA and S1PR2 with NAFLD-HCC is unclear.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The relationship between the expression of S1PR2 and the prognosis of patients suffering from NAFLD-HCC was investigated by bioinformatics techniques. Subsequently, the relationship between S1PR2 and the biological behaviours of HCC cell lines Huh 7 and HepG2 was explored by conducting molecular biology assays. Additionally, several in vivo animal experiments were carried out for the elucidation of the biological impacts of S1PR2 inhibitors on HCC cells. Finally, We used Glycodeoxycholic acid (GCDA) of CBA to explore the biological effects of CBA on HCC cell and its potential mechanism.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>High S1PR2 expression was linked to poor prognosis of the NAFLD-HCC patients. According to cellular assay results, S1PR2 expression could affect the proliferation, invasion, migration, and apoptosis of Huh 7 and HepG2 cells, and was closely associated with the G1\/G2 phase of the cell cycle. The experiments conducted in the In vivo conditions revealed that the overexpression of S1PR2 accelerated the growth of subcutaneous tumours. In addition, JTE-013, an antagonist of S1PR2, effectively inhibited the migration and proliferation of HCC cells. Furthermore, the bioinformatics analysis highlighted a correlation between S1PR2 and the PI3K\/AKT\/mTOR pathway.<\/jats:p>\n                <jats:p>GCDA administration further enhanced the expression levels of p-AKT, p-mTOR, VEGF, SGK1, and PKC\u03b1. Moreover, both the presence and absence of GCDA did not reveal any significant change in the levels of S1PR2, p-AKT, p-mTOR, VEGF, SGK1, and PKC\u03b1 proteins under S1PR2 knockdown, indicating that CBA may regulates the PI3K\/AKT\/mTOR pathway by mediating S1PR2 expression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>S1PR2 is a potential prognostic biomarker in NAFLD-HCC. In addition, We used GCDA in CBAs to treat HCC cell and found that the expression of S1PR2 was significantly increased, and the expression of PI3K\/AKT\/mTOR signalling pathway-related signal molecules was also significantly enhanced, indicating that GCDA may activate PI3K\/AKT\/mTOR signalling pathway by up-regulating the expression of S1PR2, and finally affect the activity of hepatocellular carcinoma cells. S1PR2 can be a candidate therapeutic target for NAFLD-HCC. Collectively, the findings of this research offer novel perspectives on the prevention and treatment of NAFLD-HCC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12672-023-00611-8","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T17:02:54Z","timestamp":1673456574000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Sphingosine 1-phosphate receptor 2 promotes the onset and progression of non-alcoholic fatty liver disease-related hepatocellular carcinoma through the PI3K\/AKT\/mTOR pathway"],"prefix":"10.1007","volume":"14","author":[{"given":"Ganggang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengguan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,11]]},"reference":[{"key":"611_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2022.02.002","author":"R Zheng","year":"2022","unstructured":"Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, Li L, Wei W, He J. Cancer incidence and mortality in China, 2016. J Natl Cancer Center. 2022. https:\/\/doi.org\/10.1016\/j.jncc.2022.02.002.","journal-title":"J Natl Cancer Center"},{"key":"611_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx030","author":"A Jemal","year":"2017","unstructured":"Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B, Mariotto A, Lake AJ, Wilson R, Sherman RL, et al. Annual report to the nation on the status of cancer, 1975\u20132014, featuring survival. J Natl Cancer Instit. 2017. https:\/\/doi.org\/10.1093\/jnci\/djx030.","journal-title":"J Natl Cancer Instit"},{"issue":"15","key":"611_CR3","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450\u201362.","journal-title":"N Engl J Med"},{"issue":"52","key":"611_CR4","doi-asserted-by":"publisher","first-page":"8131","DOI":"10.1016\/j.vaccine.2018.10.005","volume":"36","author":"W Yu","year":"2018","unstructured":"Yu W, Lee LA, Liu Y, Scherpbier RW, Wen N, Zhang G, Zhu X, Ning G, Wang F, Li Y, et al. Vaccine-preventable disease control in the People\u2019s Republic of China: 1949\u20132016. Vaccine. 2018;36(52):8131\u20137.","journal-title":"Vaccine"},{"issue":"12","key":"611_CR5","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1016\/j.cgh.2021.12.002","volume":"20","author":"MH Le","year":"2022","unstructured":"Le MH, Yeo YH, Li X, Li J, Zou B, Wu Y, Ye Q, Huang DQ, Zhao C, Zhang J, et al. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clinical Gastroenterol Hepatol. 2022;20(12):2809-2817.e2828.","journal-title":"Clinical Gastroenterol Hepatol"},{"issue":"24","key":"611_CR6","doi-asserted-by":"publisher","first-page":"6354","DOI":"10.1111\/febs.12446","volume":"280","author":"M Adada","year":"2013","unstructured":"Adada M, Canals D, Hannun YA, Obeid LM. Sphingosine-1-phosphate receptor 2. FEBS J. 2013;280(24):6354\u201366.","journal-title":"FEBS J"},{"issue":"2","key":"611_CR7","doi-asserted-by":"publisher","first-page":"254","DOI":"10.2174\/1871520621666210401105344","volume":"22","author":"J Long","year":"2022","unstructured":"Long J, Yao Z, Sui Y, Fang S. SphK1 promotes cancer progression through activating JAK\/STAT pathway and up-regulating S1PR1 expression in colon cancer cells. Anticancer Agents Med Chem. 2022;22(2):254\u201360.","journal-title":"Anticancer Agents Med Chem"},{"key":"611_CR8","doi-asserted-by":"publisher","first-page":"7857","DOI":"10.2147\/CMAR.S237330","volume":"12","author":"M Pang","year":"2020","unstructured":"Pang M, Li C, Zheng D, Wang Y, Wang J, Zhang W, Li F, Jing H. S1PR2 knockdown promotes migration and invasion in multiple myeloma cells via NF-\u03baB activation. Cancer Manag Res. 2020;12:7857\u201365.","journal-title":"Cancer Manag Res"},{"issue":"1","key":"611_CR9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41420-020-00390-z","volume":"7","author":"C Yang","year":"2021","unstructured":"Yang C, Yuan H, Gu J, Xu D, Wang M, Qiao J, Yang X, Zhang J, Yao M, Gu J, et al. ABCA8-mediated efflux of taurocholic acid contributes to gemcitabine insensitivity in human pancreatic cancer via the S1PR2-ERK pathway. Cell Death Discov. 2021;7(1):6.","journal-title":"Cell Death Discov"},{"issue":"9","key":"611_CR10","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/j.prp.2018.07.029","volume":"214","author":"Y Yin","year":"2018","unstructured":"Yin Y, Xu M, Gao J, Li M. Alkaline ceramidase 3 promotes growth of hepatocellular carcinoma cells via regulating S1P\/S1PR2\/PI3K\/AKT signaling. Pathol Res Pract. 2018;214(9):1381\u20137.","journal-title":"Pathol Res Pract"},{"key":"611_CR11","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-12806-4","author":"J Sarkar","year":"2022","unstructured":"Sarkar J, Aoki H, Wu R, Aoki M, Hylemon P, Zhou H, Takabe K. Conjugated bile acids accelerate progression of pancreatic cancer metastasis via S1PR2 signaling in cholestasis. Ann Surg Oncol. 2022. https:\/\/doi.org\/10.1245\/s10434-022-12806-4.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"611_CR12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3892\/ol.2022.13361","volume":"24","author":"J Yan","year":"2022","unstructured":"Yan J, Chen Y, Wu Q, Shao L, Zhou X. Expression of sphingosine-1-phosphate receptor 2 is correlated with migration and invasion of human colon cancer cells: a preliminary clinical study. Oncol Lett. 2022;24(1):241.","journal-title":"Oncol Lett"},{"issue":"9","key":"611_CR13","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1016\/j.ajpath.2018.05.015","volume":"188","author":"R Liu","year":"2018","unstructured":"Liu R, Li X, Hylemon PB, Zhou H. Conjugated bile acids promote invasive growth of esophageal adenocarcinoma cells and cancer stem cell expansion via sphingosine 1-phosphate receptor 2-mediated yes-associated protein activation. Am J Pathol. 2018;188(9):2042\u201358.","journal-title":"Am J Pathol"},{"issue":"3","key":"611_CR14","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1002\/hep.27085","volume":"60","author":"R Liu","year":"2014","unstructured":"Liu R, Zhao R, Zhou X, Liang X, Campbell DJ, Zhang X, Zhang L, Shi R, Wang G, Pandak WM, et al. Conjugated bile acids promote cholangiocarcinoma cell invasive growth through activation of sphingosine 1-phosphate receptor 2. Hepatology. 2014;60(3):908\u201318.","journal-title":"Hepatology"},{"issue":"7785","key":"611_CR15","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41586-019-1785-z","volume":"576","author":"S Hang","year":"2019","unstructured":"Hang S, Paik D, Yao L, Kim E, Trinath J, Lu J, Ha S, Nelson BN, Kelly SP, Wu L, et al. Bile acid metabolites control T(H)17 and T(reg) cell differentiation. Nature. 2019;576(7785):143\u20138.","journal-title":"Nature"},{"key":"611_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091255","author":"P Kov\u00e1cs","year":"2019","unstructured":"Kov\u00e1cs P, Csonka T, Kov\u00e1cs T, S\u00e1ri Z, Ujlaki G, Sipos A, Kar\u00e1nyi Z, Sze\u0151cs D, Heged\u0171s C, Uray K, et al. Lithocholic acid, a metabolite of the microbiome, increases oxidative stress in breast cancer. Cancers. 2019. https:\/\/doi.org\/10.3390\/cancers11091255.","journal-title":"Cancers"},{"key":"611_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/cells8040293","author":"E Mik\u00f3","year":"2019","unstructured":"Mik\u00f3 E, Kov\u00e1cs T, Seb\u0151 \u00c9, T\u00f3th J, Csonka T, Ujlaki G, Sipos A, Szab\u00f3 J, M\u00e9hes G, Bai P. Microbiome-microbial metabolome-cancer cell interactions in breast cancer-familiar, but unexplored. Cells. 2019. https:\/\/doi.org\/10.3390\/cells8040293.","journal-title":"Cells"},{"issue":"11","key":"611_CR18","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1177\/1535370214538743","volume":"239","author":"J Tsuei","year":"2014","unstructured":"Tsuei J, Chau T, Mills D, Wan YJ. Bile acid dysregulation, gut dysbiosis, and gastrointestinal cancer. Exp Biol Med. 2014;239(11):1489\u2013504.","journal-title":"Exp Biol Med"},{"issue":"7075","key":"611_CR19","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nature04330","volume":"439","author":"M Watanabe","year":"2006","unstructured":"Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, Messaddeq N, Harney JW, Ezaki O, Kodama T, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature. 2006;439(7075):484\u20139.","journal-title":"Nature"},{"issue":"5","key":"611_CR20","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00018-022-04278-2","volume":"79","author":"T Re\u017een","year":"2022","unstructured":"Re\u017een T, Rozman D, Kov\u00e1cs T, Kov\u00e1cs P, Sipos A, Bai P, Mik\u00f3 E. The role of bile acids in carcinogenesis. Cell Mol Life Sci. 2022;79(5):243.","journal-title":"Cell Mol Life Sci"},{"issue":"6","key":"611_CR21","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.dld.2010.03.015","volume":"42","author":"Maillette de Buy","year":"2010","unstructured":"de Buy Maillette, Wenniger L, Beuers U. Bile salts and cholestasis. Dig Liver Dis. 2010;42(6):409\u201318.","journal-title":"Dig Liver Dis"},{"issue":"8","key":"611_CR22","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1002\/ijc.30219","volume":"139","author":"G Xie","year":"2016","unstructured":"Xie G, Wang X, Huang F, Zhao A, Chen W, Yan J, Zhang Y, Lei S, Ge K, Zheng X, et al. Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis. Int J Cancer. 2016;139(8):1764\u201375.","journal-title":"Int J Cancer"},{"issue":"1","key":"611_CR23","doi-asserted-by":"publisher","first-page":"9227","DOI":"10.1038\/s41598-018-27521-y","volume":"8","author":"\u00c1 Nagy","year":"2018","unstructured":"Nagy \u00c1, L\u00e1nczky A, Menyh\u00e1rt O, Gy\u0151rffy B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep. 2018;8(1):9227.","journal-title":"Sci Rep"},{"issue":"3","key":"611_CR24","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","volume":"70","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM. Non-alcoholic fatty liver disease\u2014a global public health perspective. J Hepatol. 2019;70(3):531\u201344.","journal-title":"J Hepatol"},{"issue":"10290","key":"611_CR25","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290):2212\u201324.","journal-title":"Lancet"},{"issue":"6","key":"611_CR26","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1053\/j.gastro.2018.08.024","volume":"155","author":"F Kanwal","year":"2018","unstructured":"Kanwal F, Kramer JR, Mapakshi S, Natarajan Y, Chayanupatkul M, Richardson PA, Li L, Desiderio R, Thrift AP, Asch SM, et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology. 2018;155(6):1828-1837.e1822.","journal-title":"Gastroenterology"},{"key":"611_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.03.010","author":"MA Karim","year":"2022","unstructured":"Karim MA, Singal AG, Kum HC, Lee YT, Park S, Rich NE, Noureddin M, Yang JD. Clinical characteristics and outcomes of nonalcoholic fatty liver disease-associated hepatocellular carcinoma in the United States. Clin Gastroenterol Hepatol. 2022. https:\/\/doi.org\/10.1016\/j.cgh.2022.03.010.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"611_CR28","doi-asserted-by":"publisher","first-page":"108869","DOI":"10.1016\/j.jnutbio.2021.108869","volume":"100","author":"HJ Chun","year":"2022","unstructured":"Chun HJ, Shim YJ, Kwon YH. Cholic acid supplementation accelerates the progression of nonalcoholic fatty liver disease to the procarcinogenic state in mice fed a high-fat and high-cholesterol diet. J Nutr Biochem. 2022;100:108869.","journal-title":"J Nutr Biochem"},{"issue":"4","key":"611_CR29","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.bbrc.2020.07.099","volume":"530","author":"T Yoshida","year":"2020","unstructured":"Yoshida T, Tsuchiya A, Kumagai M, Takeuchi S, Nojiri S, Watanabe T, Ogawa M, Itoh M, Takamura M, Suganami T, et al. Blocking sphingosine 1-phosphate receptor 2 accelerates hepatocellular carcinoma progression in a mouse model of NASH. Biochem Biophys Res Commun. 2020;530(4):665\u201372.","journal-title":"Biochem Biophys Res Commun"},{"key":"611_CR30","doi-asserted-by":"publisher","first-page":"817028","DOI":"10.3389\/fcell.2022.817028","volume":"10","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Xia F, Yao L, Jiang B, Li X. circSSU72 promotes cell proliferation, migration and invasion of papillary thyroid carcinoma cells by targeting miR-451a\/S1PR2 axis. Front Cell Dev Biol. 2022;10:817028.","journal-title":"Front Cell Dev Biol"},{"issue":"22","key":"611_CR31","doi-asserted-by":"publisher","first-page":"5941","DOI":"10.1182\/blood-2010-08-300772","volume":"117","author":"A Salas","year":"2011","unstructured":"Salas A, Ponnusamy S, Senkal CE, Meyers-Needham M, Selvam SP, Saddoughi SA, Apohan E, Sentelle RD, Smith C, Gault CR, et al. Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A. Blood. 2011;117(22):5941\u201352.","journal-title":"Blood"},{"issue":"8","key":"611_CR32","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/emmm.201200244","volume":"4","author":"S Ponnusamy","year":"2012","unstructured":"Ponnusamy S, Selvam SP, Mehrotra S, Kawamori T, Snider AJ, Obeid LM, Shao Y, Sabbadini R, Ogretmen B. Communication between host organism and cancer cells is transduced by systemic sphingosine kinase 1\/sphingosine 1-phosphate signalling to regulate tumour metastasis. EMBO Mol Med. 2012;4(8):761\u201375.","journal-title":"EMBO Mol Med"},{"issue":"35","key":"611_CR33","doi-asserted-by":"publisher","first-page":"32841","DOI":"10.1074\/jbc.M305024200","volume":"278","author":"K Arikawa","year":"2003","unstructured":"Arikawa K, Takuwa N, Yamaguchi H, Sugimoto N, Kitayama J, Nagawa H, Takehara K, Takuwa Y. Ligand-dependent inhibition of B16 melanoma cell migration and invasion via endogenous S1P2 G protein-coupled receptor requirement of inhibition of cellular RAC activity. J Biol Chem. 2003;278(35):32841\u201351.","journal-title":"J Biol Chem"},{"issue":"9","key":"611_CR34","doi-asserted-by":"publisher","first-page":"3788","DOI":"10.1158\/0008-5472.CAN-04-2311","volume":"65","author":"D Lepley","year":"2005","unstructured":"Lepley D, Paik JH, Hla T, Ferrer F. The G protein-coupled receptor S1P2 regulates Rho\/Rho kinase pathway to inhibit tumor cell migration. Can Res. 2005;65(9):3788\u201395.","journal-title":"Can Res"},{"issue":"22","key":"611_CR35","doi-asserted-by":"publisher","first-page":"8686","DOI":"10.1158\/0008-5472.CAN-09-1110","volume":"69","author":"G Cattoretti","year":"2009","unstructured":"Cattoretti G, Mandelbaum J, Lee N, Chaves AH, Mahler AM, Chadburn A, Dalla-Favera R, Pasqualucci L, MacLennan AJ. Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation. Can Res. 2009;69(22):8686\u201392.","journal-title":"Can Res"},{"issue":"8","key":"611_CR36","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202200148RR","volume":"36","author":"RR Miao","year":"2022","unstructured":"Miao RR, Zhan S, Cui SX, Qu XJ. Intestinal aberrant sphingolipid metabolism shaped-gut microbiome and bile acids metabolome in the development of hepatic steatosis. FASEB J. 2022;36(8): e22398.","journal-title":"FASEB J"},{"issue":"5","key":"611_CR37","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/j.apsb.2021.12.011","volume":"12","author":"B Guan","year":"2022","unstructured":"Guan B, Tong J, Hao H, Yang Z, Chen K, Xu H, Wang A. Bile acid coordinates microbiota homeostasis and systemic immunometabolism in cardiometabolic diseases. Acta Pharm Sinica B. 2022;12(5):2129\u201349.","journal-title":"Acta Pharm Sinica B"},{"issue":"3","key":"611_CR38","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.molmed.2021.12.006","volume":"28","author":"MM Thibaut","year":"2022","unstructured":"Thibaut MM, Bindels LB. Crosstalk between bile acid-activated receptors and microbiome in entero-hepatic inflammation. Trends Mol Med. 2022;28(3):223\u201336.","journal-title":"Trends Mol Med"},{"issue":"1","key":"611_CR39","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.apsb.2021.07.021","volume":"12","author":"K Byrnes","year":"2022","unstructured":"Byrnes K, Blessinger S, Bailey NT, Scaife R, Liu G, Khambu B. Therapeutic regulation of autophagy in hepatic metabolism. Acta pharm Sinica B. 2022;12(1):33\u201349.","journal-title":"Acta pharm Sinica B"},{"issue":"1","key":"611_CR40","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.bbrc.2017.11.165","volume":"495","author":"Y Yu","year":"2018","unstructured":"Yu Y, Wu X, Pu J, Luo P, Ma W, Wang J, Wei J, Wang Y, Fei Z. Lycium barbarum polysaccharide protects against oxygen glucose deprivation\/reoxygenation-induced apoptosis and autophagic cell death via the PI3K\/Akt\/mTOR signaling pathway in primary cultured hippocampal neurons. Biochem Biophys Res Commun. 2018;495(1):1187\u201394.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"611_CR41","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1093\/carcin\/bgy038","volume":"39","author":"L Rosenberg","year":"2018","unstructured":"Rosenberg L, Yoon CH, Sharma G, Bertagnolli MM, Cho NL. Sorafenib inhibits proliferation and invasion in desmoid-derived cells by targeting Ras\/MEK\/ERK and PI3K\/Akt\/mTOR pathways. Carcinogenesis. 2018;39(5):681\u20138.","journal-title":"Carcinogenesis"},{"key":"611_CR42","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3389\/fnmol.2011.00051","volume":"4","author":"J Karar","year":"2011","unstructured":"Karar J, Maity A. PI3K\/AKT\/mTOR pathway in angiogenesis. Front Mol Neurosci. 2011;4:51.","journal-title":"Front Mol Neurosci"},{"issue":"3","key":"611_CR43","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10549-018-4697-y","volume":"169","author":"RLB Costa","year":"2018","unstructured":"Costa RLB, Han HS, Gradishar WJ. Targeting the PI3K\/AKT\/mTOR pathway in triple-negative breast cancer: a review. Breast Cancer Res Treat. 2018;169(3):397\u2013406.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"611_CR44","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.pharmthera.2013.12.004","volume":"142","author":"J Polivka Jr","year":"2014","unstructured":"Polivka J Jr, Janku F. Molecular targets for cancer therapy in the PI3K\/AKT\/mTOR pathway. Pharmacol Ther. 2014;142(2):164\u201375.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"611_CR45","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/hep.24681","volume":"55","author":"E Studer","year":"2012","unstructured":"Studer E, Zhou X, Zhao R, Wang Y, Takabe K, Nagahashi M, Pandak WM, Dent P, Spiegel S, Shi R, et al. Conjugated bile acids activate the sphingosine-1-phosphate receptor 2 in primary rodent hepatocytes. Hepatology. 2012;55(1):267\u201376.","journal-title":"Hepatology"},{"issue":"2","key":"611_CR46","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.apsb.2014.12.009","volume":"5","author":"E Kwong","year":"2015","unstructured":"Kwong E, Li Y, Hylemon PB, Zhou H. Bile acids and sphingosine-1-phosphate receptor 2 in hepatic lipid metabolism. Acta Pharm Sinica B. 2015;5(2):151\u20137.","journal-title":"Acta Pharm Sinica B"},{"issue":"4","key":"611_CR47","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/hep.27592","volume":"61","author":"M Nagahashi","year":"2015","unstructured":"Nagahashi M, Takabe K, Liu R, Peng K, Wang X, Wang Y, Hait NC, Wang X, Allegood JC, Yamada A, et al. Conjugated bile acid-activated S1P receptor 2 is a key regulator of sphingosine kinase 2 and hepatic gene expression. Hepatology. 2015;61(4):1216\u201326.","journal-title":"Hepatology"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-023-00611-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-023-00611-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-023-00611-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T18:09:30Z","timestamp":1673460570000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-023-00611-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,11]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["611"],"URL":"https:\/\/doi.org\/10.1007\/s12672-023-00611-8","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,11]]},"assertion":[{"value":"2 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The approval for the animal experimental protocol involving 4-week-old balb\/c nude mice (Hangzhou Ziyuan Experimental Animal Technology Co., Ltd) was acquired from the ethical review committee of Zhongshan Hospital Qingpu Branch, Fudan University, which was in accordance with the Guide for the Care and Use of Laboratory Animals (Approval No. 2020\u201341).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}